The company reported the commercial availability of Daybue for Rett syndrome in adult & pediatric patients aged ≥2yrs. in the US. Daybue is supplied as a strawberry-flavored oral solution containing 200mg of trofinetide per mL
Daybue was approved in the US for Rett syndrome, based on a P-III study (LAVENDER) study in female patients aged 5-20yrs. Trofinetide showed an increased branching of dendrites and synaptic plasticity signals in animal studies
The company offers a patient support program i.e., Acadia Connect that provides the access to eligible patients with Daybue & offers personal assistance, financial resources & prescription support to patients & caregivers starting & continuing appropriate Daybue therapy
Ref: Businesswire | Image: Acadia
Related News:- Acadia’s Daybue (trofinetide) Receives the US FDA’s Approval for Rett Syndrome in Adult and Pediatric Patients Aged ≥2Years
